224
Heidel JD, Davis ME (2011) Clinical developments in nanotechnology for cancer therapy. Pharm
Res 28:187–199
Hinterwirth H, Stübiger G, Lindner W, Lämmerhofer M (2013) Gold nanoparticle-conjugated
anti-oxidized low-density lipoprotein antibodies for targeted lipidomics of oxidative stress biomarkers. Anal Chem 85:8376–8384
Holder AL, Goth-Goldstein R, Lucas D, Koshland CP (2012) Particle-induced artifacts in the MTT
and LDH viability assays. Chem Res Toxicol 25:1885–1892
Hu W, Culloty S, Darmody G, Lynch S, Davenport J, Ramirez-Garcia S, Dawson K, Lynch I,
Doyle H, Sheehan D (2015) Neutral red retention time assay in determination of toxicity of
nanoparticles. Mar Environ Res 111:158–161
Huang XL, Li LL, Liu TL, Hao NJ, Liu HY, Chen D, Tang FQ (2011) The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS
Nano 5:5390–5399
Jaiswal P, Gidwani B, Vyas A (2016) Nanostructured lipid carriers and their current application in
targeted drug delivery. Artif Cells Nanomed Biotechnol 44:27–40
Jing X, Park JH, Peters TM, Thorne PS (2015) Toxicity of copper oxide nanoparticles in lung
epithelial cells exposed at the air-liquid interface compared with in vivo assessment. Toxicol
in Vitro 29:502–511
Jo DH, Kim JH, Lee TG, Kim JH (2015) Size, surface charge, and shape determine therapeutic
effects of nanoparticles on brain and retinal diseases. Nanomedicine 11:1603–1611
Jorgensen I, Rayamajhi M, Miao EA (2017) Programmed cell death as a defence against infection.
Nat Rev Immunol 17:151–164
Kim K, Song J, Kim M, Chung S, Jeong J, Yang J, Choi A, Choi H, Oh J (2014) Physicochemical
analysis methods for nanomaterials considering their toxicological evaluations. Mol Cell
Toxicol 10:347–360
Kim IY, Joachim E, Choi H, Kim K (2015) Toxicity of silica nanoparticles depends on size, dose,
and cell type. Nanomed Nanotechnol Biol Med 11:1407–1416
Klaper R, Arndt D, Bozich J, Dominguez G (2014) Molecular interactions of nanomaterials and
organisms: defining biomarkers for toxicity and high-throughput screening using traditional
and next-generation sequencing approaches. Analyst 139:882–895
Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer
J, Westendorf AM (2013) Immunization with biodegradable nanoparticles efficiently induces
cellular immunity and protects against influenza virus infection. J Immunol 190:6221–6229
Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM (1995) Variable estimates of cytokine
levels produced by commercial ELISA kits: results using international cytokine standards. J
Immunol Methods 186:171–179
Lee PY, Wong KK (2011) Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv
8:245–253
Liu Y, Miyoshi H, Nakamura M (2007) Nanomedicine for drug delivery and imaging: a promising
avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer
120:2527–2537
Love SA, Maurer-Jones MA, Thompson JW, Lin Y-S, Haynes CL (2012) Assessing nanoparticle toxicity. In: Cooks RG, Yeung ES (eds) Annual review of analytical chemistry, vol 5,
pp 181–205
Lv M, Huang W, Chen Z, Jiang H, Chen J, Tian Y, Zhang Z, Xu F (2015) Metabolomics techniques
for nanotoxicity investigations. Bioanalysis 7:1527–1544
Mahant S, Rao R, Souto EB, Nanda S (2020) Analytical tools and evaluation strategies for nanostructured lipid carrier based topical delivery systems. Expert Opin Drug Deliv
Mahler GJ, Esch MB, Tako E, Southard TL, Archer SD, Glahn RP, Shuler ML (2012) Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol 7:264–271
Manshian BB, Soenen SJ, Al-Ali A, Brown A, Hondow N, Wills J, Jenkins GJ, Doak SH (2015)
Cell type-dependent changes in CdSe/ZnS quantum dot uptake and toxic endpoints. Toxicol
Sci 144:246–258
M. C. Teixeira et al.
Heidel JD, Davis ME (2011) Clinical developments in nanotechnology for cancer therapy. Pharm
Res 28:187–199
Hinterwirth H, Stübiger G, Lindner W, Lämmerhofer M (2013) Gold nanoparticle-conjugated
anti-oxidized low-density lipoprotein antibodies for targeted lipidomics of oxidative stress biomarkers. Anal Chem 85:8376–8384
Holder AL, Goth-Goldstein R, Lucas D, Koshland CP (2012) Particle-induced artifacts in the MTT
and LDH viability assays. Chem Res Toxicol 25:1885–1892
Hu W, Culloty S, Darmody G, Lynch S, Davenport J, Ramirez-Garcia S, Dawson K, Lynch I,
Doyle H, Sheehan D (2015) Neutral red retention time assay in determination of toxicity of
nanoparticles. Mar Environ Res 111:158–161
Huang XL, Li LL, Liu TL, Hao NJ, Liu HY, Chen D, Tang FQ (2011) The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS
Nano 5:5390–5399
Jaiswal P, Gidwani B, Vyas A (2016) Nanostructured lipid carriers and their current application in
targeted drug delivery. Artif Cells Nanomed Biotechnol 44:27–40
Jing X, Park JH, Peters TM, Thorne PS (2015) Toxicity of copper oxide nanoparticles in lung
epithelial cells exposed at the air-liquid interface compared with in vivo assessment. Toxicol
in Vitro 29:502–511
Jo DH, Kim JH, Lee TG, Kim JH (2015) Size, surface charge, and shape determine therapeutic
effects of nanoparticles on brain and retinal diseases. Nanomedicine 11:1603–1611
Jorgensen I, Rayamajhi M, Miao EA (2017) Programmed cell death as a defence against infection.
Nat Rev Immunol 17:151–164
Kim K, Song J, Kim M, Chung S, Jeong J, Yang J, Choi A, Choi H, Oh J (2014) Physicochemical
analysis methods for nanomaterials considering their toxicological evaluations. Mol Cell
Toxicol 10:347–360
Kim IY, Joachim E, Choi H, Kim K (2015) Toxicity of silica nanoparticles depends on size, dose,
and cell type. Nanomed Nanotechnol Biol Med 11:1407–1416
Klaper R, Arndt D, Bozich J, Dominguez G (2014) Molecular interactions of nanomaterials and
organisms: defining biomarkers for toxicity and high-throughput screening using traditional
and next-generation sequencing approaches. Analyst 139:882–895
Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer
J, Westendorf AM (2013) Immunization with biodegradable nanoparticles efficiently induces
cellular immunity and protects against influenza virus infection. J Immunol 190:6221–6229
Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM (1995) Variable estimates of cytokine
levels produced by commercial ELISA kits: results using international cytokine standards. J
Immunol Methods 186:171–179
Lee PY, Wong KK (2011) Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv
8:245–253
Liu Y, Miyoshi H, Nakamura M (2007) Nanomedicine for drug delivery and imaging: a promising
avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer
120:2527–2537
Love SA, Maurer-Jones MA, Thompson JW, Lin Y-S, Haynes CL (2012) Assessing nanoparticle toxicity. In: Cooks RG, Yeung ES (eds) Annual review of analytical chemistry, vol 5,
pp 181–205
Lv M, Huang W, Chen Z, Jiang H, Chen J, Tian Y, Zhang Z, Xu F (2015) Metabolomics techniques
for nanotoxicity investigations. Bioanalysis 7:1527–1544
Mahant S, Rao R, Souto EB, Nanda S (2020) Analytical tools and evaluation strategies for nanostructured lipid carrier based topical delivery systems. Expert Opin Drug Deliv
Mahler GJ, Esch MB, Tako E, Southard TL, Archer SD, Glahn RP, Shuler ML (2012) Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol 7:264–271
Manshian BB, Soenen SJ, Al-Ali A, Brown A, Hondow N, Wills J, Jenkins GJ, Doak SH (2015)
Cell type-dependent changes in CdSe/ZnS quantum dot uptake and toxic endpoints. Toxicol
Sci 144:246–258
M. C. Teixeira et al.